An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Tilman Oltersdorf(Harvard University), Saul H. Rosenberg(Abbott Fund), Paul Nimmer(Abbott Fund), Jürgen Dinges(Abbott Fund), David G. Nettesheim(Abbott Fund), Anthony Letai(Dana-Farber Cancer Institute), Barbara Belli, Craig B. Thompson(Memorial Sloan Kettering Cancer Center), Anatol Oleksijew(Abbott Fund), Milan Bruncko(Abbott Fund), Michael Wendt(Abbott Fund), Andrew M. Petros(Abbott Fund), Aaron Kunzer(Abbott Fund), Baole Wang(Abbott Fund), Chi Li(South China Normal University), Shen Wang(Abbott Fund), Haichao Zhang(Abbott Fund), Shi-Chung Ng(Abbott Fund), John C. Reed(University of North Carolina at Chapel Hill), Stephen K. Tahir(Abbott Fund), Robert C. Armstrong, Steven W. Elmore(AbbVie (United States)), Stanley J. Korsmeyer(Howard Hughes Medical Institute), Thomas L. Deckwerth, Kevin J. Tomaselli, Alexander R. Shoemaker(Abbott Fund), Mary K. Joseph(Abbott Fund), Michael J. Mitten(Abbott Fund), Shinichi Kitada(Sanford Burnham Prebys Medical Discovery Institute), Philip J. Hajduk(Abbott Fund), David J. Augeri(Abbott Fund), Jacqueline M. O’Connor(Abbott Fund), Stephen W. Fesik(Vanderbilt University)
Cited by 3,384
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
IAP family proteins---suppressors of apoptosis
|Genes & Development|1999|2.5k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k